- Home
- IPA vs LSB Comparison
IPA vs LSB Comparison
Compare IPA & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- LSB
- Stock Information
- Founded
- IPA 1983
- LSB 2002
- Country
- IPA United States
- LSB China
- Employees
- IPA N/A
- LSB N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- LSB
- Sector
- IPA Health Care
- LSB
- Exchange
- IPA Nasdaq
- LSB NYSE
- Market Cap
- IPA 22.4M
- LSB 22.3M
- IPO Year
- IPA 2017
- LSB N/A
- Fundamental
- Price
- IPA $0.70
- LSB $1.00
- Analyst Decision
- IPA Strong Buy
- LSB
- Analyst Count
- IPA 2
- LSB 0
- Target Price
- IPA $4.00
- LSB N/A
- AVG Volume (30 Days)
- IPA 524.9K
- LSB 13.8K
- Earning Date
- IPA 07-28-2025
- LSB 06-21-2025
- Dividend Yield
- IPA N/A
- LSB N/A
- EPS Growth
- IPA N/A
- LSB N/A
- EPS
- IPA N/A
- LSB N/A
- Revenue
- IPA $16,581,105.00
- LSB $79,415,311.00
- Revenue This Year
- IPA $4.67
- LSB $39.33
- Revenue Next Year
- IPA $14.15
- LSB $75.61
- P/E Ratio
- IPA N/A
- LSB N/A
- Revenue Growth
- IPA 1.34
- LSB N/A
- 52 Week Low
- IPA $0.27
- LSB $0.36
- 52 Week High
- IPA $1.08
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- IPA 81.29
- LSB 30.09
- Support Level
- IPA $0.50
- LSB $0.99
- Resistance Level
- IPA $0.58
- LSB $1.09
- Average True Range (ATR)
- IPA 0.05
- LSB 0.07
- MACD
- IPA 0.01
- LSB 0.02
- Stochastic Oscillator
- IPA 83.10
- LSB 27.81
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.